Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults 18 to 64 years of age at time of first vaccination, inclusive.~* Good general health as assessed by medical history and physical examination.~* Access to a consistent means of telephone contact~* Written informed consent obtained from the subject.~* Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~Exclusion Criteria:~* Presence of significant acute or chronic, uncontrolled medical or psychiatric illness~* Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.~* Blood pressure abnormalities~* Diagnosed with cancer, or treatment for cancer, within 3 years.~* Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible.~* Persons with a history of histologically-confirmed basal cell carcinoma of the skin successfully treated with local excision only are excepted and may enroll, but other histologic types of skin cancer are exclusionary.~* Women who are disease-free 3 years or more after treatment for breast cancer and receiving long-term prophylactic tamoxifen are excepted and may enroll.~* Presence of an oral temperature ≥ 37.8º C, or acute symptoms greater than mild severity on the scheduled date of first vaccination.~* Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.~* Receipt of cytotoxic or immunosuppressive drug within 6 months of study enrollment.~* Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin.~* Administration of any non-influenza vaccines within 30 days before study enrollment or during the study period.~* Use of any investigational or non-registered product (drug or vaccine) or planned participation in another investigational study within 30 days prior to study enrollment, or during the study period.~* Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period.~* Any known or suspected allergy to any constituent of influenza vaccines.~* Known pregnancy or a positive urine beta-human chorionic gonadotropin (ß-hCG) test result prior to dosing on Study Days 0 or 21.~* Lactating or nursing.~* Women of child bearing potential who lack a history of reliable contraceptive practices.~* Known receipt of analgesic or antipyretic medication on the day of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Pumarix Formulation 1 Group (Type: EXPERIMENTAL): Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 1 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
- Pumarix Formulation 2 Group (Type: EXPERIMENTAL): Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 2 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
- Pumarix Formulation 3 Group (Type: EXPERIMENTAL): Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 3 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
- Pandemrix Formulation A Group (Type: EXPERIMENTAL): Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation A of Pandemrix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
- Pandemrix Formulation B Group (Type: EXPERIMENTAL): Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation B of Pandemrix ™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
- Pumarix Formulation 4 Group (Type: EXPERIMENTAL): Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 4 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
- Pumarix Formulation 5 Group (Type: EXPERIMENTAL): Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 5 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete